BAYZF - Menopause Management: Bayer's Non-Hormonal Treatment Option Shows Efficacy In Trial | Benzinga
Monday, Bayer AG (OTC: BAYRY (OTC: BAYZF) announced topline results of Phase 3 studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo.
Elinzanetant is a first dual neurokinin-1,3 (NK-1,3) receptor antagonist, as a non-hormonal treatment of moderate to severe VMS associated with menopause, administered orally once daily.
Elinzanetant met all four primary endpoints in both studies, demonstrating statistically significant reductions in the frequency and severity of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) from baseline to week ...